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Main points 
This retrospective analysis of health record data from 42,298 UK adults aged ≥65 presenting to 
primary care with a UTI found no evidence that compared to nitrofurantoin, empirical cefalexin, 
ciprofloxacin or co-amoxiclav prescribing was associated with a reduced risk of sepsis or death. 
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Abstract 
Background 
Nitrofurantoin is widely recommended for empirical treatment of urinary tract infection (UTI) but 
primary care clinicians may prescribe alternative antibiotics to improve prognosis in older, sicker 
patients. We assessed if prescribing alternative antibiotics was associated with reduced risk of 
adverse outcomes in older patients. 
Methods 
This retrospective cohort study included patients aged ≥65 years empirically treated for a UTI with 
nitrofurantoin, cefalexin, ciprofloxacin or co-amoxiclav. We matched patients on their propensity to 
receive a nitrofurantoin prescription and used mixed effects logistic regression to estimate odds 
ratios (OR) and 95% confidence intervals (CI) for re-consultation and re-prescription (proxy for 
treatment failure), hospitalisation for UTI, sepsis, or acute kidney injury (AKI), and death.  
Results 
We identified 42,298 patients aged ≥65 years prescribed empirical nitrofurantoin, cefalexin, 
ciprofloxacin or co-amoxiclav for a UTI. Compared to nitrofurantoin, patients prescribed cefalexin, 
ciprofloxacin or co-amoxiclav had lower odds of re-consultation and re-prescription (OR for 
cefalexin; 0.85 95% CI 0.75-0.98; OR for ciprofloxacin; 0.48, 95% CI 0.38-0.61, OR for co-amoxiclav; 
0.77, 95% CI 0.64-0.93). Patients prescribed cefalexin or ciprofloxacin had greater odds of 
hospitalisation for sepsis (OR for cefalexin; 1.89, 95% CI 1.03-3.47; OR for ciprofloxacin 3.21, 95% CI 
1.59 – 6.50), and patients prescribed cefalexin had greater odds of death (OR 1.44, 95% CI 1.12-
1.85).  
Conclusions 
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Compared to nitrofurantoin, prescribing of alternative antibiotics for UTI in older people may be 
associated with lower rates of treatment failure but was not associated with reduced risk of UTI-
related hospitalisation or death.   
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Introduction 
Urinary tract infection (UTI) is the most common indication for antibiotic prescribing in older adults 
presenting to ambulatory care services [1] and those in long-term care facilities.[2-4] Around 60-75% 
of adults presenting with suspected UTI receive empirical antibiotic therapy at the same 
consultation, without knowledge of microbiological susceptibilities.[5-7] Current clinical guidelines in 
the United States [8] and United Kingdom [9] recommend nitrofurantoin for empirical treatment of 
uncomplicated UTI. However, previous research found that around 15% of older adults empirically 
treated for a UTI in primary care were prescribed cefalexin, ciprofloxacin or co-amoxiclav.[10] 
Cefalexin, ciprofloxacin and co-amoxiclav are broad-spectrum antibiotics, and are associated with 
increased rates of drug-related adverse events [11] and antibiotic-associated diarrhoea. [12] They 
are also more likely to select for drug-resistant organisms leading to subsequent antibiotic resistant 
colonisation or infection.[8] Qualitative research found that primary care clinicians were more likely 
to consider broad-spectrum antibiotics for older patients, who were frail, had co-morbidities, and 
were judged to have more severe illness. [13] The perceived aim of broad-spectrum antibiotic 
prescribing was to prevent treatment failure, worsening illness, and hospitalisation, events thought 
to be more likely if narrow-spectrum antibiotics were prescribed for that clinical scenario.[13]  
Meta-analysis of three randomised trials (n=289) found similar clinical cure rates between patients 
with UTI treated with nitrofurantoin versus flouroquinolones, suggesting that flouroquinolones offer 
little additional benefit.[14] However, trials only included young, healthy women and were 
underpowered to assess risk of important but rare outcomes such as UTI-related hospitalisation or 
death.[15-17] Previous observational studies have compared trimethoprim-sulfamethoxazole with 
flouroquinolones, and sulfamethiazole with pivmecillinam but no trials or observational studies have 
compared nitrofurantoin with cefalexin or co-amoxiclav.[18, 19]   
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We therefore used data from anonymised linked health records to compare the risk of adverse 
outcomes in adults aged ≥65 prescribed empirical nitrofurantoin versus cefalexin, ciprofloxacin or 
co-amoxiclav for suspected UTI in primary care. Our aim was to assess whether cefalexin, 
ciprofloxacin or co-amoxiclav were associated with a reduced risk of treatment failure, 
hospitalisation for UTI, sepsis or acute kidney injury (AKI), or death. If these antibiotics were 
associated with risks that were similar or higher than those of nitrofurantoin, then this would 
support further reductions in their use, even in older, frailer, comorbid patients with more severe 
presenting features.  
Method 
Data Source 
We used the Clinical Practice Research Datalink (CPRD), an electronic database of anonymised 
primary care records, covering 11.3 million patients from 674 general practices across the UK.[20] 
Approximately 7% of the UK population are included and patients are broadly representative of the 
wider UK population in terms of age, gender and ethnicity. The CPRD holds data on demographics, 
clinical encounters and diagnoses (coded using Read codes), drug prescriptions, blood tests and 
referrals to specialists. Data are available once they have met a series of quality checks on 
completeness and reliability and the CPRD deems them to be of the standard required for research 
purposes. Linked hospital and death registration data is available for patients from approximately 
50% of contributing English practices. Hospital diagnoses and causes of death are recorded using 
version 10 of the International Classification of Disease (ICD-10). 
The CPRD Independent Scientific Advisory Committee approved the study protocol (protocol 
number 17_250). Further ethical approval was not required as the proposed research was within the 
remit of the CPRD’s broad National Research Ethics Service approval. We used the Reporting of 
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Studies Conducted using Observational Routinely-collected Health Data (RECORD) statement and 
checklist to guide study reporting.[21] 
Design and participants 
This was a retrospective cohort study using linked health record data. Patients were eligible for 
inclusion if, between 1st January 2010 and 31st December 2016, their data were of the quality 
required by CPRD, they were ≥65 years old, and eligible for data-linkage. Only patients registered 
with practices that consented to data-linkage had linked hospital and death registry data. We 
excluded patients if they were temporary residents or had gaps in their data coverage. Follow-up 
began from the latest of, study start date (1st January 2010), patient’s 65th birthday, six months after 
they registered with the practice (to avoid including historical UTIs recorded at registration), or the 
date their practice met the CPRD data quality requirements. Follow-up ended on the earliest of 
study end date (31st December 2016), the day the patient died or transferred out of the practice (i.e. 
last date of CPRD data collection), or 28 days after an incident UTI event. We identified eligible 
patients with a Read code indicating an incident primary care presentation with a suspected UTI 
(codes available in Supplementary Appendix 1), and a same-day prescription code indicating 
empirical prescribing of a relevant antibiotic. We defined ‘incident’ as a consultation occurring in a 
patient without a UTI-related Read code or trimethoprim or nitrofurantoin prescription in the 
preceding 90 days (trimethoprim and nitrofurantoin are used almost exclusively for UTI in the UK). 
We used the first incident episode during each patient’s follow-up period. We excluded UTI episodes 
with a hospital discharge in the preceding 14 days to exclude hospital-acquired infections.   
Exposures 
The exposure variable was the recorded empirical antibiotic prescription. 
Outcomes 
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We estimated risk of the following adverse outcomes for patients empirically treated in primary care 
for an incident suspected UTI: 
1. Re-consultation for urinary symptoms and a same-day antibiotic re-prescription within 14 
days following the incident UTI, as a proxy for treatment failure, ascertained through Read 
and prescription codes recorded in primary care records. 
2. Hospitalisation for UTI, sepsis, or acute kidney injury (AKI) within 14 days following the 
incident UTI ascertained from ICD-10 codes recorded in linked hospital admission data for 
the first episode of a hospital admission, i.e., the episode most likely responsible for the 
admission. 
3. Death within 28 days following the incident UTI using linked death registration data. 
We chose 14 days for the re-consultation and hospitalisatio  outcomes to increase the likelihood 
that these events were related to the initial UTI. Longer time periods increase the likelihood that the 
outcome may have been influenced by an intervening event, e.g., if a 28 day period was used, a 
patient could have a UTI, recover, have a cardiac event and be hospitalised with AKI. We chose 28 
days for the death outcome as the UTI could precipitate events (e.g., sepsis) which take some time 
to evolve before death.  
Statistical Analyses 
We used primary care demographic and clinical codes to describe baseline characteristics for 
patients by prescribed antibiotic. To compare outcomes between patients prescribed nitrofurantoin 
versus cefalexin, ciprofloxacin or co-amoxiclav, we matched patients on their propensity to receive a 
nitrofurantoin prescription. Variables included in the logistic regression models that generated the 
propensity score were age, Index of Multiple Deprivation score quintile [22], Charlson score [23], the 
presence or absence of a Read code indicating coronary heart disease, renal disease, respiratory 
disease, type 2 diabetes mellitus, heart failure, peripheral arterial disease, and stroke, as these 
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variables were previously shown to be associated with antibiotic prescribing.[7, 24] We also included 
gender, whether the patient was housebound, had dementia, liver disease, rheumatoid arthritis, 
cancer, urinary incontinence or a urinary catheter, an estimated glomerular filtration rate (eGFR), 
and polypharmacy, (defined as records indicating ≥5 long-term medications per month in the year 
prior to the incident UTI), as these variables could be associated with both the clinical decision 
around choice of antibiotic, and the UTI-related outcomes. 
We used nearest neighbour matching with no replacement to match three patients with 
nitrofurantoin prescriptions to one patient with a cefalexin prescription. We assessed balance in 
measured baseline covariates between matched groups by visually inspecting jitter plots and 
histograms of covariate distribution before and after matching, and by calculating standardised 
mean differences for covariates between groups. We regarded standardised mean differences of 
<0.1 as reflecting adequate balance.[25, 26] We used mixed effects logistic regression [27] to 
calculated odds ratios (OR) and 95% confidence intervals (CI) for each outcome, accounting for 
clustering by general practice. We repeated the analyses by matching three patients with 
nitrofurantoin prescriptions to one patient with a ciprofloxacin prescription, and then three patients 
with nitrofurantoin prescriptions to one patient with a co-amoxiclav prescription. 
Results     
From a cohort of 795,484 patients aged 65 and over, we identified 123,607 (16%) with an incident 
empirically treated UTI, of whom 42,298 were prescribed nitrofurantoin, cefalexin, ciprofloxacin or 
co-amoxiclav (Figure 1). In this final cohort, 11,420 (27%) patients were male and the median age at 
time of incident UTI was 76 years (interquartile range, 70-83). Nitrofurantoin was the most 
commonly prescribed antibiotic, accounting for 60% of all prescriptions, followed by cefalexin (18%), 
co-amoxiclav (13%) and ciprofloxacin (9%).  
Baseline characteristics 
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There were differences in baseline characteristics across the antibiotic groups. For example, 55% of 
the ciprofloxacin group were male compared to 23% of the nitrofurantoin group (Table 1). 
Compared to the nitrofurantoin group, greater proportions of the cefalexin, ciprofloxacin and co-
amoxiclav groups had co-morbidities, particularly ischaemic heart disease, heart failure, and renal 
disease. Around 3% of the nitrofurantoin group had a Charlson score of ≥6, compared to 5-6% of the 
other groups.  
Propensity-score matching 
We matched 21,600 patients prescribed nitrofurantoin with 7200 patients prescribed cefalexin, 
11,151 patients prescribed nitrofurantoin with 3717 patients prescribed ciprofloxacin, and 15,786 
patients prescribed nitrofurantoin with 5262 patients prescribed co-amoxiclav (Table 2). Inspection 
of jitter plots and histograms suggested matching had improved balance of covariates across the two 
groups. Standardised mean differences were all less than 0.1. 
Risk of adverse outcomes 
Compared to nitrofurantoin, patients prescribed cefalexin, ciprofloxacin or co-amoxiclav had lower 
odds of re-consultation and re-prescription (OR for cefalexin; 0.85, 95% CI 0.75-0.98, p=0.020; OR for 
ciprofloxacin; 0.48, 95% CI 0.38-0.61, p=<0.001; OR for co-amoxiclav; 0.77, 95% CI 0.64-0.93, 
p=0.006) (Table 2). We found no significant difference in the odds of hospitalisation for UTI between 
patients prescribed nitrofurantoin versus cefalexin, ciprofloxacin or co-amoxiclav. However, 
compared to nitrofurantoin, patients prescribed ciprofloxacin had greater odds of hospitalisation for 
sepsis (OR 3.21, 95% CI 1.59 – 6.50, p=0.001), as did patients prescribed cefalexin (OR 1.89, 95% CI 
1.03-3.47, p=0.038). We found no significant difference in the odds of hospitalisation for AKI 
between patients prescribed nitrofurantoin versus cefalexin, ciprofloxacin or co-amoxiclav. 
Compared to nitrofurantoin, patients prescribed cefalexin had greater odds of death within 28 days 
of the UTI (OR 1.44, 95% CI 1.12-1.85, p=0.004).  
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Sensitivity analyses 
The association between patients prescribed ciprofloxacin or cefalexin and lower odds of re-
consultation and re-prescription could be due to the significantly increased rates of sepsis 
hospitalisation (ciprofloxacin) and death (cefalexin) in these groups, preventing patients’ re-
presenting to primary care. We therefore combined these three outcomes and found that 7.1% of 
patients prescribed nitrofurantoin re-consulted or were hospitalised for sepsis or died, compared to 
6.3% of patients prescribed ciprofloxacin or cefalexin, with an adjusted OR for the combined 
outcome of 0.87 (95% CI 0.78-0.95).  
Discussion 
Our results show that patients prescribed cefalexin, ciprofloxacin or co-amoxiclav had lower odds of 
re-consultation and re-prescription. Patients prescribed cefalexin or ciprofloxacin had greater odds 
of sepsis hospitalisation, and those prescribed cefalexin had greater odds of death. Overall, 
compared to nitrofurantoin, we found no evidence that cefalexin, ciprofloxacin or co-amoxiclav 
were associated with a reduction in the risk of UTI-related hospitalisation or death. 
Results in context 
The lower odds of re-consultation and re-prescription amongst patients prescribed cefalexin, 
ciprofloxacin or co-amoxiclav may reflect lower odds of treatment failure. This was in contrast to 
previous trials that generally showed similar clinical cure rates between narrow and broad-spectrum 
agents.[16, 28, 29] This association remained significant when we combined the re-consultation and 
re-prescription outcome with hospitalisation for sepsis or death, suggesting that, despite the higher 
rates of sepsis/death in the cefalexin/ciprofloxacin group, there remain a group of patients who 
were less likely to experience treatment failure with these agents. However, we were unable to 
distinguish whether patients in the nitrofurantoin group who re-consulted and received another 
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antibiotic prescription did so because of an adverse event or intolerance, rather than for treatment 
failure. 
We found increased odds of sepsis in patients prescribed cefalexin or ciprofloxacin. This finding may 
be due to residual unmeasured confounding because these patients were sicker or had more 
complicated infection. It may also relate to higher levels of prior fluoroquinolone exposure, 
previously shown to be associated with increased sepsis risk, possibly due to disruption of the gut 
microbiome and subsequent dysregulation of the immune response to infection. [30] 
Our finding of an increased risk of death in patients prescribed cefalexin is intriguing. There are 
several possible explanations. The antibiotic itself may increase the risk of death, particularly in this 
cohort, many of whom had multiple co-morbidities and were prescribed multiple other drugs. This is 
not implausible; cefalexin use is associated with antibiotic associated diarrhoea and clostridium 
difficile infection, which may result in serious and protracted illness in elderly co-morbid 
patients.[31]  It may also be due to antimicrobial resistance. For example, the 2017 English 
Surveillance Programme for Antimicrobial Utilisation and Resistance report showed that 10% of 
community-acquired E.coli UTIs were resistant to cefalexin, but only 2% to nitrofurantoin.[32]  
Finally, some of these findings could again be due to residual confounding. Patients prescribed 
cefalexin may have been less healthy, presented with more severe illness, and were therefore more 
likely to experience an adverse outcome irrespective of the prescribed antibiotic. Thus, it may be 
more appropriate to regard the exposure as a combination of patient and prescription factors, which 
is why we have related associations to the “patients prescribed cefalexin”, rather than the 
prescription alone.  
Strengths and weaknesses of this study 
We used data from a general practice database that is broadly representative of the UK 
population.[20] Cohort entry was dependent on presentation and empirical treatment of UTI in 
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primary care, and thus reduced indication bias. We also reduced indication bias by propensity-score 
matching and achieving adequate balance of baseline characteristics across the groups. 
Our study has some limitations. We attempted to capture patients presenting with UTI but had no 
microbiological data to support this. However, whilst a limitation, this is also more representative of 
clinical practice. Our outcomes, particularly sepsis and AKI, relied on coding and were not 
microbiologically or biochemically confirmed. We were unable to determine precise reasons for re-
consultation and re-prescription and acknowledge that not all of these events may have been due to 
treatment failure. We were unable to determine antibiotic treatment duration and therefore could 
not include this potentially important variable in the propensity score model. Based on current 
definitions [8], some patients may have presented with ‘complicated’ UTI, for which the 
recommended treatment includes some of the alternative antibiotics assessed. Therefore, we have 
not commented on the appropriateness (or not) of the prescribed agent. Our findings are based on 
prescriptions and not on dispensed or ingested drugs.  Finally, despite our design, differential coding, 
indication bias and residual confounding may have affected our findings. 
Clinical implications 
Our findings highlight the challenges associated with selecting antibiotics for older patients with 
suspected UTI. Compared to nitrofurantoin, we found no evidence that cefalexin, ciprofloxacin or co-
amoxiclav prescribing was associated with a  reduced risk of hospitalisation or death, suggesting that 
the perceived aim expressed by clinicians in previous qualitative work was not being achieved, and 
thus supporting further reductions in prescribing of these agents, even in frailer, sicker patients, 
especially given their impact on antimicrobial resistance. Future research should explore reasons for 
continued use of these antibiotics for UTI in primary care and provide clinicians with information on 
which patients are most likely to benefit from their use. 
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Figure legends 
 
Figure 1. Flow of patients from initial identification in the database through to final cohort. 
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Tables 
Table 1. Baseline characteristics by prescribed antibiotic. Values are numbers (%) unless otherwise 
stated. 
 Cefalexin Ciprofloxacin Co-amoxiclav Nitrofurantoin 
N 7546 (17.8) 3868 (9.1) 5516 (13.0) 25368 (60.0) 
Men 2150 (28.5) 2115 (54.7) 2229 (40.4) 5930 (23.4) 
Mean (SD) age 77.5 (8.4) 76.5 (8.3) 77.6 (8.5) 76.5 (8.4) 
Mean (SD) follow-up time (years) 4.2 (2.0) 4.5 (2.0) 4.2 (2.0) 4.6 (1.9) 
Mean (SD) prescription duration 
(days) 
8.2 (7.0) 7.6 (7.0) 8.3 (8.6) 6.6 (3.6) 
Index of multiple deprivation 
decile 
1 or 2 (least deprived) 
3 or 4 
5 or 6 
7 or 8 
9 or 10 (most deprived) 
 
 
1708 (22.6) 
1710 (22.7) 
1722 (22.8) 
1254 (16.6) 
1152 (15.3) 
 
 
1056 (27.3) 
957 (24.7) 
850 (22.0) 
605 (15.6) 
400 (10.3) 
 
 
1354 (24.5) 
1401 (25.4) 
1255 (22.8) 
849 (15.4) 
657 (11.9) 
 
 
6850 (27.0) 
6180 (24.4) 
5214 (20.6) 
3970 (15.6) 
3154 (12.4) 
Housebound 41 (5.5) 136 (3.5) 265 (4.8) 929 (3.7) 
Respiratory disease 1702 (22.6) 849 (21.9) 1198 (21.7) 5339 (21.0) 
Cardiac failure 516 (6.8) 212 (5.5) 347 (6.3) 1083 (4.3) 
Dementia 512 (6.8) 170 (4.4) 382 (6.9) 1439 (5.7) 
Peripheral vascular disease 488 (6.5) 252 (6.5) 321 (5.8) 1082 (4.3) 
Renal disease 2243 (29.7) 1001 (25.9) 1499 (27.2) 5310 (20.9) 
Rhuematoid arthritis 297 (3.9) 108 (2.8) 188 (3.4) 900 (3.5) 
Cancer 1295 (17.2) 780 (20.2) 949 (17.2) 3889 (15.3) 
Stroke 886 (11.7) 392 (10.1) 673 (12.2) 2460 (9.7) 
Diabetes 1474 (19.5) 783 (20.2) 1111 (20.1) 4234 (16.7) 
Liver disease 68 (0.9) 30 (0.8) 36 (0.7) 171 (0.7) 
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Ischaemic heart disease 1602 (21.2) 821 (21.2) 1158 (21.0) 4290 (16.9) 
Urinary catheter 372 (4.9) 309 (8.0) 327 (5.9) 853 (3.4) 
Urinary incontinence 1199 (15.9) 471 (12.2) 867 (15.7) 3972 (15.7) 
Polypharmacy 3299 (43.7) 1540 (39.8) 2376 (43.1) 9301 (36.7) 
eGFR 
60-90 
45-59 
30-44 
15-29 
<15 
missing 
 
4168 (55.2) 
1749 (23.2) 
917 (12.2) 
319 (4.2) 
47 (0.6) 
346 (4.6) 
 
2344 (60.6) 
811 (21.0) 
388 (10.0) 
148 (3.8) 
26 (0.7) 
151 (3.9) 
 
3170 (57.5) 
1227 (22.2) 
613 (11.1) 
208 (3.8) 
44 (0.8) 
254 (4.6) 
 
16719 (65.9) 
5237 (20.6) 
1815 (7.2) 
391 (1.5) 
41 (0.2) 
1165 (4.6) 
Charlson score 
0 
1 
2 
3 
4 
5 
≥6 
 
2029 (26.9) 
1515 (20.1) 
1406 (18.6) 
1070 (14.2) 
658 (8.7) 
428 (5.7) 
440 (5.8) 
 
1073 (27.7) 
765 (19.8) 
773 (20.0) 
535 (13.8) 
313 (8.1) 
197 (5.1) 
212 (5.5) 
 
1591 (28.8) 
1098 (19.9) 
1006 (18.2) 
769 (13.9) 
437 (7.9) 
305 (5.5) 
310 (5.6) 
 
8845 (34.9) 
5354 (21.1) 
4755 (18.7) 
3050 (12.0) 
1567 (6.2) 
955 (3.8) 
842 (3.3) 
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Table 2. Propensity-score matched analyses comparing outcomes between nitrofurantoin and other antibiotics.  
 Cefalexin (n=7200) versus 
nitrofurantoin (n=21,600) 
Ciprofloxacin (n=3717) versus 
nitrofurantoin (n=11,151) 
Co-amoxiclav (n=5262) versus 
nitrofurantoin (n=15,786) 
Outcomes OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Re-consultation and re-prescription 
within 14 days 
0.85 (0.75-0.98) 0.020 0.48 (0.38-0.61) <0.001 0.77 (0.64-0.93) 0.006 
Hospitalised for UTI within 14 days 0.96 (0.78-1.18) 0.673 0.84 (0.57-1.26) 0.408 0.94 (0.68-1.31) 0.731 
Hospitalised for sepsis within 14 days 1.89 (1.03 - 3.47) 0.038 3.21 (1.59-6.50) 0.001 1.91 (0.98-3.73) 0.058 
Hospitalised for AKI within 14 days 0.55 (0.23-1.31) 0.175 1.53 (0.49-4.79) 0.457 0.87 (0.40-1.90) 0.727 
Death within 28 days 1.44 (1.12 – 1.85) 0.004 1.18 (0.83-1.68) 0.353 1.39 (0.93-2.07) 0.108 
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Figure 1 
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